miR-17–92 cluster is connected with disease progression and oxaliplatin/capecitabine chemotherapy efficacy in advanced gastric cancer patients: A preliminary study

This study aimed to determine the role of plasma miR-17–92 cluster level in predicting chemoresistance in patients with gastric cancer (GC) undergoing oxaliplatin/capecitabine (XELOX) chemotherapy. Patients recently diagnosed with advanced GC were chosen as participants based on the inclusion criter...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Baohua, Shen, Cunfang, Wu, Milu, Zhao, Junhui, Guo, Qijing, Luo, Yushuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392796/
https://www.ncbi.nlm.nih.gov/pubmed/30170406
http://dx.doi.org/10.1097/MD.0000000000012007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392796/
https://www.ncbi.nlm.nih.gov/pubmed/30170406
http://dx.doi.org/10.1097/MD.0000000000012007

Ejemplares similares